The Latest Breaking News from Amyotrophic lateral sclerosis

Toronto Maple Leafs great Borje Salming, who passed away on Thursday from nervous disease amyotrophic lateral sclerosis (ALS), succumbed unusually quickly to the disease less than four months after diagnosis, his doctor told Swedish broadcaster SVT.

Amylyx Pharmaceuticals Inc.’s controversial treatment for amyotrophic lateral sclerosis won the support of a panel of U.S. regulatory advisers, putting the product on track for likely clearance.

Ichiro Hatanaka, a former employee of the Japan External Trade Organization (JETRO), who was told he had a limited life expectancy after being diagnosed with ALS (amyotrophic lateral sclerosis), has established a foundation to support others fighting the disease.

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD). Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC. Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast…

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders.

Stealth BioTherapeutics (NASDAQ: MITO) presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.

Stealth BioTherapeutics Corp (NASDAQ:MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  The data were presented at the Keystone Neurodegeneration Symposium. A Phase 1 study to evaluate the safety and tolerability…

The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals  (NASDAQ: AMLX) for its lead drug candidate AMX0035 with regard to the treatment of patients with amyotrophic lateral sclerosis (ALS).

Voyager Therapeutics Inc (NASDAQ:VYGR) will present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction at the American Society of Gene and Cell Therapy Annual Meeting. Voyager's TRACER capsid discovery platform has identified a novel AAV9-derived capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and…